B-Diagnostic_tool	0	12	Angiographic
O	13	16	and
B-Diagnostic_tool	17	24	optical
I-Diagnostic_tool	25	34	coherence
I-Diagnostic_tool	35	46	tomographic
O	47	54	results
O	55	57	of
O	58	61	the
O	62	68	MARINA
O	69	74	study
O	75	77	of
O	78	89	ranibizumab
O	90	92	in
B-Disease	93	104	neovascular
I-Disease	105	108	age
I-Disease	108	109	-
I-Disease	109	116	related
I-Disease	117	124	macular
I-Disease	125	137	degeneration
O	137	138	.

O	140	142	To
O	143	149	assess
O	150	165	pharmacodynamic
O	166	175	responses
O	176	178	to
O	179	190	ranibizumab
O	190	191	,
O	192	194	an
O	195	204	inhibitor
O	205	207	of
O	208	216	vascular
O	217	228	endothelial
O	229	235	growth
O	236	242	factor
O	243	244	A
O	245	246	(
O	246	250	VEGF
O	250	251	-
O	251	252	A
O	252	253	)
O	253	254	,
O	255	257	in
O	258	259	a
O	260	265	study
O	266	268	of
O	269	272	the
O	273	282	treatment
O	283	285	of
O	286	295	minimally
O	296	303	classic
O	304	306	or
O	307	313	occult
O	314	318	with
O	319	321	no
B-Symptom	322	329	classic
I-Symptom	330	339	choroidal
I-Symptom	340	358	neovascularization
O	359	368	secondary
O	369	371	to
B-Disease	372	375	age
I-Disease	375	376	-
I-Disease	376	383	related
I-Disease	384	391	macular
I-Disease	392	404	degeneration
O	405	406	(
B-Disease	406	409	AMD
O	409	410	)
O	411	412	(
O	412	422	designated
O	423	429	MARINA
O	430	431	[
O	431	440	Minimally
O	441	448	Classic
O	448	449	/
O	449	455	Occult
O	456	461	Trial
O	462	464	of
O	465	468	the
O	469	473	Anti
O	473	474	-
O	474	478	VEGF
O	479	487	Antibody
O	488	499	Ranibizumab
O	500	502	in
O	503	506	the
O	507	516	Treatment
O	517	519	of
B-Disease	520	531	Neovascular
I-Disease	532	535	AMD
O	535	536	]
O	536	537	)
O	538	541	and
O	542	544	to
O	545	552	compare
O	553	558	these
O	559	568	responses
O	569	573	with
O	574	579	those
O	580	582	in
O	583	584	a
O	585	589	sham
O	589	590	-
O	590	599	injection
O	600	607	control
O	608	613	group
O	613	614	.

O	615	628	Retrospective
O	629	630	(
O	630	642	prespecified
O	643	646	and
O	647	649	ad
O	650	653	hoc
O	653	654	)
O	655	663	analyses
O	664	666	of
O	667	669	24
O	669	670	-
O	670	675	month
O	676	680	data
O	680	681	.

O	682	687	Seven
O	688	695	hundred
O	696	703	sixteen
O	704	712	patients
O	712	713	,
O	714	724	randomized
O	725	727	to
O	728	729	0
O	729	730	.
O	730	731	3
O	731	732	-
O	732	734	mg
O	735	746	ranibizumab
O	747	748	(
O	748	749	n
O	750	751	=
O	752	755	238
O	755	756	)
O	756	757	,
O	758	759	0
O	759	760	.
O	760	761	5
O	761	762	-
O	762	764	mg
O	765	776	ranibizumab
O	777	778	(
O	778	779	n
O	780	781	=
O	782	785	240
O	785	786	)
O	786	787	,
O	788	790	or
O	791	792	a
O	793	797	sham
O	798	807	injection
O	808	809	(
O	809	810	n
O	811	812	=
O	813	816	238
O	816	817	)
O	817	818	.

B-Diagnostic_tool	819	831	Stereoscopic
I-Diagnostic_tool	832	838	fundus
I-Diagnostic_tool	839	850	photography
O	851	854	and
B-Diagnostic_tool	855	866	fluorescein
I-Diagnostic_tool	867	878	angiography
O	879	880	(
B-Diagnostic_tool	880	882	FA
O	882	883	)
O	884	888	were
O	889	893	done
O	894	896	at
O	897	905	baseline
O	906	909	and
O	910	916	months
O	917	918	3
O	918	919	,
O	920	921	6
O	921	922	,
O	923	925	12
O	925	926	,
O	927	930	and
O	931	933	24
O	933	934	.

B-Diagnostic_tool	935	942	Optical
I-Diagnostic_tool	943	952	coherence
I-Diagnostic_tool	953	963	tomography
O	964	965	(
B-Diagnostic_tool	965	968	OCT
O	968	969	)
O	970	973	was
O	974	983	performed
O	984	986	at
O	987	988	a
O	989	995	subset
O	996	998	of
O	999	1012	investigative
O	1013	1018	sites
O	1019	1020	(
O	1020	1022	46
O	1023	1031	patients
O	1031	1032	)
O	1033	1035	at
O	1036	1044	baseline
O	1044	1045	,
O	1046	1049	day
O	1050	1051	7
O	1051	1052	,
O	1053	1056	and
O	1057	1063	months
O	1064	1065	1
O	1066	1069	and
O	1070	1072	12
O	1072	1073	.

O	1074	1086	Prespecified
O	1087	1096	secondary
O	1097	1100	end
O	1101	1107	points
O	1108	1112	were
O	1113	1117	mean
O	1118	1124	change
O	1125	1129	from
O	1130	1138	baseline
O	1139	1141	in
B-Characteristic	1142	1147	total
I-Characteristic	1148	1152	area
I-Characteristic	1153	1155	of
I-Characteristic	1156	1165	choroidal
I-Characteristic	1166	1184	neovascularization
O	1185	1188	and
B-Characteristic	1189	1194	total
I-Characteristic	1195	1199	area
I-Characteristic	1200	1202	of
I-Characteristic	1203	1210	leakage
I-Characteristic	1211	1215	from
I-Characteristic	1216	1225	choroidal
I-Characteristic	1226	1244	neovascularization
O	1245	1247	at
O	1248	1254	months
O	1255	1257	12
O	1258	1261	and
O	1262	1264	24
O	1264	1265	.

O	1266	1278	Prespecified
O	1279	1290	exploratory
B-Diagnostic_tool	1291	1293	FA
O	1294	1297	end
O	1298	1304	points
O	1305	1313	included
B-Characteristic	1314	1318	mean
I-Characteristic	1319	1325	change
I-Characteristic	1326	1330	from
I-Characteristic	1331	1339	baseline
I-Characteristic	1340	1342	in
I-Characteristic	1343	1346	the
I-Characteristic	1347	1352	areas
I-Characteristic	1353	1355	of
I-Characteristic	1356	1359	the
I-Characteristic	1360	1369	choroidal
I-Characteristic	1370	1388	neovascularization
I-Characteristic	1389	1395	lesion
O	1396	1399	and
B-Symptom	1400	1406	serous
I-Symptom	1407	1414	sensory
I-Symptom	1415	1422	retinal
I-Symptom	1423	1433	detachment
O	1434	1435	(
B-Symptom	1435	1439	SSRD
O	1439	1440	)
O	1441	1443	at
O	1444	1450	months
O	1451	1453	12
O	1454	1457	and
O	1458	1460	24
O	1460	1461	.

O	1462	1466	Post
O	1467	1470	hoc
O	1471	1482	exploratory
B-Diagnostic_tool	1483	1485	FA
O	1486	1493	outcome
O	1494	1502	measures
O	1503	1511	included
O	1512	1515	the
O	1516	1526	proportion
O	1527	1529	of
O	1530	1538	patients
O	1539	1543	with
O	1544	1546	no
B-Symptom	1547	1554	leakage
I-Symptom	1555	1559	from
I-Symptom	1560	1569	choroidal
I-Symptom	1570	1588	neovascularization
O	1589	1592	and
O	1593	1597	mean
O	1598	1604	change
O	1605	1609	from
O	1610	1618	baseline
O	1619	1623	over
O	1624	1628	time
O	1629	1631	in
O	1632	1635	the
O	1636	1640	area
O	1641	1643	of
B-Symptom	1644	1654	subretinal
I-Symptom	1655	1662	fibrous
I-Symptom	1663	1669	tissue
I-Symptom	1669	1670	/
I-Symptom	1670	1679	disciform
I-Symptom	1680	1684	scar
O	1684	1685	.

O	1686	1689	The
O	1690	1702	prespecified
O	1703	1714	exploratory
O	1715	1718	end
O	1719	1724	point
O	1725	1728	for
B-Diagnostic_tool	1729	1732	OCT
O	1733	1736	was
O	1737	1741	mean
O	1742	1748	change
O	1749	1753	from
O	1754	1762	baseline
O	1763	1767	over
O	1768	1772	time
O	1773	1775	in
B-Characteristic	1776	1782	center
I-Characteristic	1783	1788	point
I-Characteristic	1789	1798	thickness
O	1798	1799	.

O	1800	1802	At
O	1803	1805	12
O	1806	1809	and
O	1810	1812	24
O	1813	1819	months
O	1819	1820	,
O	1821	1834	statistically
O	1835	1846	significant
O	1847	1855	benefits
O	1856	1858	of
O	1859	1870	ranibizumab
O	1871	1875	over
O	1876	1880	sham
O	1881	1890	treatment
O	1891	1895	were
O	1896	1904	observed
O	1905	1908	for
O	1909	1913	mean
O	1914	1920	change
O	1921	1925	from
O	1926	1934	baseline
O	1935	1937	in
O	1938	1941	the
O	1942	1947	areas
O	1948	1950	of
B-Symptom	1951	1960	choroidal
I-Symptom	1961	1979	neovascularization
I-Symptom	1980	1986	lesion
O	1986	1987	,
B-Characteristic	1988	1993	total
I-Characteristic	1994	2003	choroidal
I-Characteristic	2004	2022	neovascularization
O	2022	2023	,
B-Symptom	2024	2031	leakage
I-Symptom	2032	2036	from
I-Symptom	2037	2046	choroidal
I-Symptom	2047	2065	neovascularization
O	2065	2066	,
B-Symptom	2067	2071	SSRD
O	2071	2072	,
O	2073	2076	and
B-Symptom	2077	2086	disciform
I-Symptom	2087	2091	scar
I-Symptom	2091	2092	/
I-Symptom	2092	2102	subretinal
I-Symptom	2103	2111	fibrosis
O	2111	2112	.

O	2113	2115	At
O	2116	2118	12
O	2119	2125	months
O	2126	2127	(
O	2127	2132	final
B-Diagnostic_tool	2133	2136	OCT
O	2136	2137	)
O	2137	2138	,
O	2139	2142	the
B-Characteristic	2143	2147	mean
I-Characteristic	2148	2154	change
I-Characteristic	2155	2157	in
I-Characteristic	2158	2164	foveal
I-Characteristic	2165	2171	center
I-Characteristic	2172	2177	point
I-Characteristic	2178	2187	thickness
O	2188	2190	on
B-Diagnostic_tool	2191	2194	OCT
O	2195	2198	was
O	2199	2200	a
O	2201	2212	significant
O	2213	2221	decrease
O	2222	2224	in
O	2225	2228	the
O	2229	2240	ranibizumab
O	2241	2246	group
O	2247	2255	compared
O	2256	2260	with
O	2261	2264	the
O	2265	2269	sham
O	2270	2275	group
O	2275	2276	.

O	2277	2285	Patients
O	2286	2290	with
O	2291	2300	minimally
O	2301	2308	classic
O	2309	2311	or
O	2312	2318	occult
O	2319	2323	with
O	2324	2326	no
B-Disease	2327	2334	classic
I-Disease	2335	2346	neovascular
I-Disease	2347	2350	AMD
O	2351	2358	treated
O	2359	2363	with
O	2364	2375	ranibizumab
O	2376	2388	demonstrated
O	2389	2400	improvement
O	2401	2405	that
O	2406	2409	was
O	2410	2420	consistent
O	2421	2424	for
B-Diagnostic_tool	2425	2431	visual
I-Diagnostic_tool	2432	2438	acuity
O	2438	2439	,
B-Diagnostic_tool	2440	2442	FA
O	2442	2443	,
O	2444	2447	and
B-Diagnostic_tool	2448	2451	OCT
O	2452	2460	outcomes
O	2461	2464	and
O	2465	2473	superior
O	2474	2476	to
O	2477	2481	that
O	2482	2484	in
O	2485	2489	sham
O	2489	2490	-
O	2490	2497	treated
O	2498	2506	patients
O	2506	2507	.
